Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YS247 (Neo-DC) Vaccine in Metastatic Castration-Resistant Prostate Cancer
NCT07583160Phase 1Enrolling by invitation
- Sponsor
- Changhai Hospital
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YS247 in castration-resistant prostate cancer (CRPC), sponsored by Changhai Hospital. Primary endpoints: Incidence of Dose-Limiting Toxicities at 60 days, Incidence and Severity of Treatment-Emergent Adverse Events at 60 days and 1 more. Started Jun 2026; status: enrolling by invitation.
02
Drugs
YS247
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT07583160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07583160.